Stuart Scott

Dr. Stuart Scott

1. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029
+1
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2015 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
JHJ. Kevin Hicks
J. Kevin Hicks
JBJeffrey R. Bishop
Jeffrey R. Bishop
KSKatrin Sangkuhl
Katrin Sangkuhl
DMDaniel J. Müller
Daniel J. Müller
YJYuan Ji
Yuan Ji
AGAndrea Gaedigk
Andrea Gaedigk

22 May 2013 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
Stuart ScottStuart Scott
Stuart Scott
KSK Sangkuhl
K Sangkuhl
CSC M Stein
C M Stein
JHJean-Sébastien Hulot
Jean-Sébastien Hulot
JMJ L Mega
J L Mega
ASA R Shuldiner
A R Shuldiner
Cytochrome P450 (CYP)2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites, resulting in reduced platelet inhibition. In addition, CYP2C19 loss‐of‐function alleles confer increased risks for serious adverse cardiovascular (CV) events among clopidogrel‐treated patients with acute coronary syndromes (ACSs) undergoing percutaneous coronary intervention (PCI). Guideline updates include emphasis on appropriate indication for CYP2C19 genotype–directed antiplatelet therapy, refined recommendations for specific CYP2C19 alleles, and additional evidence from an expanded literature review (updates at http://www.pharmgkb.org). Clinical Pharmacology & Therapeutics (2013); 94 3, 317–323. doi:10.1038/clpt.2013.105

11 June 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
CRCarolina Roselli
Carolina Roselli
MCMark D. Chaffin
Mark D. Chaffin
LWLu-Chen Weng
Lu-Chen Weng
SAStefanie Aeschbacher
Stefanie Aeschbacher
GAGustav Ahlberg
Gustav Ahlberg
PEPatrick T. Ellinor
Patrick T. Ellinor

7 September 2011 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
JJJ A Johnson
J A Johnson
LGL Gong
L Gong
MWMichelle Whirl-Carrillo
Michelle Whirl-Carrillo
BGB F Gage
B F Gage
Stuart ScottStuart Scott
Stuart Scott
RAR B Altman
R B Altman

1 February 2017 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
KCKelly E Caudle
Kelly E Caudle
HDHenry Dunnenberger
Henry Dunnenberger
RFRobert R. Freimuth
Robert R. Freimuth
JPJosh F. Peterson
Josh F. Peterson
JBJonathan D. Burlison
Jonathan D. Burlison
JHJames M. Hoffman
James M. Hoffman
Reporting and sharing pharmacogenetic test results across clinical laboratories and electronic health records is a crucial step toward the implementation of clinical pharmacogenetics, but allele function and phenotype terms are not standardized. Our goal was to develop terms that can be broadly applied to characterize pharmacogenetic allele function and inferred phenotypes. Terms currently used by genetic testing laboratories and in the literature were identified. The Clinical Pharmacogenetics Implementation Consortium (CPIC) used the Delphi method to obtain a consensus and agree on uniform terms among pharmacogenetic experts. Experts with diverse involvement in at least one area of pharmacogenetics (clinicians, researchers, genetic testing laboratorians, pharmacogenetics implementers, and clinical informaticians; n = 58) participated. After completion of five surveys, a consensus (>70%) was reached with 90% of experts agreeing to the final sets of pharmacogenetic terms. The proposed standardized pharmacogenetic terms will improve the understanding and interpretation of pharmacogenetic tests and reduce confusion by maintaining consistent nomenclature. These standard terms can also facilitate pharmacogenetic data sharing across diverse electronic health care record systems with clinical decision support. Genet Med 19 2, 215–223.